Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

CRISPR, Casebia link with StrideBio

by Ann M. Thayer
April 24, 2017 | A version of this story appeared in Volume 95, Issue 17

CRISPR Therapeutics and Casebia Therapeutics are working with StrideBio to find adeno-associated viral (AAV) vectors for in vivo CRISPR/Cas9-based therapies. Casebia is a joint venture between CRISPR Therapeutics and Bayer. StrideBio will use its structure-guided evolution methods to develop AAV vectors with improved tissue specificity and reduced susceptibility to immune responses. Its technology comes from the work of Aravind Asokan at the University of North Carolina, Chapel Hill, and Mavis Agbandje-McKenna at the University of Florida.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.